Curriculum Vitae

KADAM ASHOK B
Flat No. 302, Siddesh Enclave, Sect 12,
Khopar Khairne, Navi Mumbai – 400 709

Contact : +91-9004673179 / +91-9833406813
E-mail : ka.ashokkadam@gmail.com

Objective:

To obtain a full-time job in the field of medicinal chemistry, active pharmaceutical ingredient (API) research or custom contract manufacturing, where I can utilize my knowledge, skill and experience.

Overview:

I have 25 years of experience in pharmaceutical industry and have worked on both new chemical entity (NCE) and active pharmaceutical ingredient (API) research. I joined medicinal chemistry division of Glenmark Research Centre, Mahape in 2002 after working with RPG Life Sciences, Navi Mumbai (1.5 years) and USV Ltd., Mumbai (4 years) in the field of process development. At Glenmark, my job focus has been mainly on identifying and developing new route of synthesis for entirely new molecules designed as agonist/antagonist of therapeutic targets of interest. I am also responsible for scale up of lead molecules for PKDM and in-vivo profiling. My job responsibilities also include training and guiding junior colleagues and monitor day-to-day activities of the laboratory. I have gained good exposure to API process development and scale-up at plant sites during my stint with RPG Life Sciences and USV Ltd. I have co-authored seven PCT publications and a research publication in a peer reviewed international journal. I have worked on two proprietary molecules of Glenmark, which were out-licensed -one to Merck KGaA and other Sanofi-Aventis.

Educational Qualification

1 M. Sc. Organic Chemistry, 1997 – First class (62.4%)
Institute of Science, Mumbai, University of Mumbai

2 B. Sc. Chemistry, 1995 – First class (77.8%)
Modern College, University of Mumbai, Mumbai

3 HSC (State Board), 1992 – First class (61.67%)
Rajarshi Chhatrapati Shahu College, Kolhapur

4 SSC (State Board) 1990 – First class (61%)
Mahatma Gandhi Vidyalaya School, Savlaj, Sangli

Career History and Achievements

Glenmark Pharmaceuticals Ltd., Navi Mumbai (Sept 2002 – present)

Joined Glenmark Pharmaceutical Ltd. as a Research Associate in drug discovery department. Promoted to Research Officer in 2004. Promoted to Senior Research Officer in 2007. Promoted to Research Scientist in 2010. Promoted to Senior Research Scientist in 2016.

I worked on multistep synthesis of small molecule agonists/antagonist of several therapeutic targets such as DPP4, TRPV3, TRPA1, TRPM8, ROR gamma t, CB1 and MAP4K1. A large number of molecules were prepared in several scaffolds to arrive at meaningful structure-activity relationship.

I also worked extensively on Transient receptor potential (TRP) cation channel inhibitors. Synthesized several small molecule inhibitors of TRPV3, TRPM8 and TRPA1. In the TRPV3 project, I worked on several different scaffolds. GRC 15300, the lead candidate showed excellent efficacy in inflammatory, neuropathic and osteoarthritic pain. Apart from the above projects, I have contributed significantly towards the synthesis of RORyt inhibitors and CB1 agonists. As a part of immuno-

	oncology project, I am currently working on synthesis of molecules from two different scaffolds as antagonists of MAP4K1. Two lead molecules shows low nanomolar potency in in-vitro assay.
US Vitamin Ltd., Mumbai (July 1999 – Aug 2002)	Worked as a Research Associate at US Vitamin Ltd. Mumbai. Worked majorly on process development of scale up of Famciclovir, Valaciclovir and Simvastatin. Involved in developing novel, non-infringing and cost effective route of synthesis for these products.
RPG Life Sciences, Mumbai (Nov 1997 – June 1999)	Worked as a Trainee Chemist at SEARL India Ltd., Navi Mumbai, presently known as RPG Life Sciences Ltd. Worked on process development of Deltamethrin, Pritilachlor, Enalapril and 2-methylaziridine phosphine oxide (MAPO). Deltamethrin and MAPO projects were successfully commercialized.

List of Patent Publications

1 Fused imidazole Carboxamides as TRPV3 modulators.
Sachin S Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha P Patil, **Ashok B Kadam**, Vishal G Deshmukh, Sachin V Dhone, Rajendra P Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay. **WO2010109287A1**, September 30, 2010.

2 Processes for the preparation of DPP IV inhibitors
Abraham Thomas, V. S. Prasada Rao Lingam, **Ashok B Kadam**, Suresh M. Kadam, Shantaram K Phatangare, Deepak V Ukride. **US7893103B2**, February 22, 2011.

3 Chromenone derivatives as TRPV3 antagonists
Sachin S Chaudhari, Abraham Thomas, **Ashok B Kadam**, Sachin V Dhone, Bharat G Adik, Neelima Khairatkar-Joshi, Vidya G Kattige. **US20110237659A1**, September 29, 2011.

4 Fused pyrimidine-dione derivatives as Trpa1 modulators
Sachin S Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha P Patil, **Ashok B Kadam**, Vishal G Deshmukh, Sachin V Dhone, Rajendra P Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay. **US20120041004A1**, February 16, 2012.

5 Fused pyrimidine-dione derivatives as trpa1 modulators
Sachin S Chaudhari, Sukeerthi Kumar, Abraham Thomas, Nisha P Patil, **Ashok B Kadam**, Vishal G Deshmukh, Sachin V Dhone, Rajendra P Chikhale, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay. **US20140128603A1,** May 8, 2014.

6 Fused pyrimidine-dione derivatives as TRPA1 modulators
Abraham Thomas, **Ashok B Kadam**, Indranil Mukhopadhyay, Neelima Khairatkar-Joshi, Nisha P Patil, Rajendra P Chikhale, Sachin S Chaudhari, Sachin V Dhone, Sukeerthi Kumar, Vishal G Deshmukh. **US9000159.** July 4, 2015.

7 Aryl and Heteroaryl ether compounds as ROR gamma modulators.
Chaudhari Sachin S, Thomas Abraham, **Kadam Ashok B**, Dhone Sachin V, Adik Bharat G, Khairatkar-joshi, Neelima, Shah Daisy M, Bajpai Malini. **US09718817**, January 8, 2017.

Research Paper Publication

Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1′H-spiro[chromene-2,4′-piperidine]-1′-carboxamides as TRPM8 antagonists Chaudhari, S. S.; **Kadam, A. B**.; Khairatkar-Joshi, N.; Mukhopadhyay, I.; Karnik, P. V.; Raghuram, A.; Rao, S. S.; Vaiyapuri, T. S.; Wale, D. P.; Bhosale, V. M.; Gudi, G. S. Sangana, R. R.; Thomas, A. *Bioorganic & Medicinal Chemistry* **2013**, *21*, 6542–6553. doi: 10.1016/j.bmc.2013.08.031. Epub 2013 Aug 29.